Comparison of Longitudinal Plasma Assays in Relation to Longitudinal Amyloid Pathology in Alzheimer’s Disease

Abstract

Background: Blood‐based biomarkers of AD, especially p ‐tau217, show high concordance with Aβ‐PET load and status. While many studies relied on cross‐sectional data, assessing dynamic changes in these assays is important for future clinical use and trial outcomes.